文献速递乳腺癌

IMpassion130 试验中阿替利珠单抗联合白蛋白紫杉醇治疗转移性三阴性乳腺癌的患者报告结局

Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
PubMed 文献 · Ann Oncol · 2020-02-20

IMpassion130 是一项 III 期试验,在转移性三阴性乳腺癌(mTNBC)患者中比较阿替利珠单抗+白蛋白紫杉醇(A+nP)与安慰剂+白蛋白紫杉醇(Pl+nP)的疗效。患者报告结局(PRO)分析显示,在 PD-L1 阳性患者中,两臂的健康相关生活质量(HRQoL)、躯体功能和角色功能的至恶化时间(TTD)无差异,且治疗相关症状(疲劳、腹泻、恶心/呕吐)的临床意义恶化无差异。结论认为 A+nP 一线治疗延迟疾病进展且不损害患者日常功能或 HRQoL,也不加重治疗症状。

要点

  • A+nP 一线治疗 mTNBC 不损害 HRQoL 或日常功能。
  • PD-L1+ 患者中两臂 HRQoL 至恶化时间无差异(HR 0.94)。
  • 两臂治疗相关症状(疲劳、腹泻、恶心/呕吐)的临床意义恶化无差异。

核心结论

  • A+nP 一线治疗 mTNBC 延迟疾病进展,且不损害患者日常功能或 HRQoL,也不加重治疗相关症状。

研究设计与样本

  • III 期 IMpassion130 试验,患者接受阿替利珠单抗(840 mg)或安慰剂每 2 周联合白蛋白紫杉醇(100 mg/m²)每 28 天周期第 1、8、15 天给药。
  • 患者每周期第 1 天完成 EORTC QLQ-C30 和 QLQ-BR23 问卷,治疗结束时及 1 年随访期间每 4 周完成。
  • HRQoL 至恶化时间(TTD,定义为基线下降≥10 分持续两个周期)为次要终点,功能 TTD 和症状评分为探索性终点。

主要发现

  • PD-L1+ 患者中,两臂 HRQoL 至恶化时间无差异(HR 0.94,95%CI 0.69-1.28)。
  • PD-L1+ 患者中,躯体功能(HR 1.02,95%CI 0.76-1.37)和角色功能(HR 0.77,95%CI 0.57-1.04)的至恶化时间无差异。
  • A+nP 与 Pl+nP 的基线 HRQoL 平均分(67.5 对 65.0)、躯体功能(82.8 对 79.4)和角色功能(73.7 对 71.7)相当,治疗期间无≥10 分的临床意义变化。
  • 两臂治疗相关症状(疲劳、腹泻、恶心/呕吐)的临床意义恶化无差异。
  • 意向治疗(ITT)人群结果与 PD-L1+ 人群相似。

关键数值与推荐

  • HRQoL 至恶化时间定义为基线评分下降≥10 分且持续两个周期。
  • 基线 PRO 完成率:QLQ-C30 为 92%,QLQ-BR23 为 89%,至第 20 周期在 ITT 和 PD-L1+ 患者中保持>80%。

临床怎么用

  • 对于 PD-L1+ mTNBC 患者,A+nP 一线治疗在延迟进展的同时可维持生活质量和日常功能。
  • 治疗期间疲劳、腹泻、恶心/呕吐等症状的临床意义恶化与安慰剂联合方案相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metastatic triple-negative breast cancer (mTNBC) is incurable. A key treatment goal is providing palliation while maintaining patients' health-related quality of life (HRQoL). IMpassion130 demonstrated progression-free survival benefit with atezolizumab + nab-paclitaxel (A + nP) versus placebo + nab-paclitaxel (Pl + nP) in first-line treatment of mTNBC patients with programmed death-ligand 1 positive (PD-L1+) tumors. We report data on patient-reported outcomes (PROs), which capture patient perspectives of treatment. PATIENTS AND METHODS: Patients with untreated advanced or mTNBC received atezolizumab (840 mg) or placebo every 2 weeks in combination with nab-paclitaxel (100 mg/m2) on days 1, 8, and 15 of each 28-day cycle until progression or intolerance. Patients completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) and its Breast Cancer Module (QLQ-BR23) on day 1 of each cycle, at end of treatment, and every 4 weeks during 1 year of follow-up. Time-to-deterioration (TTD) in HRQoL (first ≥10-point decrease from baseline lasting two cycles) was a secondary end point. Exploratory end points included TTD in functioning and mean and mean change from baseline scores in HRQoL, functioning, and disease- and treatment-related symptoms. RESULTS: Baseline completion of PROs was 92% (QLQ-C30) and 89% (QLQ-BR23) and remained >80% through cycle 20 in intent-to-treat (ITT) and PD-L1+ patients. No differences between arms in median TTD in PD-L1+ patients were observed for HRQoL {hazard ratio (HR) 0.94 [95% confidence interval (CI) 0.69-1.28]} or physical [HR 1.02 (95% CI 0.76-1.37)] or role [HR 0.77 (95% CI 0.57-1.04)] functioning. Mean baseline scores for A + nP versus Pl + nP for HRQoL (67.5 versus 65.0) and physical (82.8 versus 79.4) and role (73.7 versus 71.7) functioning were comparable between arms and throughout the course of treatment, with no clinically meaningful (≥10 point) changes from baseline until patients discontinued treatment. No differences in clinically meaningful worsening in treatment symptoms (fatigue, diarrhea, or nausea/vomiting) were observed between arms. Results in ITT patients were similar. CONCLUSIONS: A + nP as first-line treatment for mTNBC delayed progression without compromising patients' day-to-day functioning or HRQoL or worsening treatment symptoms. CLINICALTRIAL. GOV IDENTIFIER: NCT02425891.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Adams S, Diéras V, Barrios CH, et al. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer. Ann Oncol. 2020. PMID: 32178964. doi:10.1016/j.annonc.2020.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。